FRANKFURT (Reuters) – Biotechnology company BioNTech said Monday that it had expanded an ongoing global pivot in its COVID-19 candidate vaccine to include evidence in its home country, Germany.
The German vaccine regulator, the Paul Ehrlich Institute, has approved the 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and his wife Pfizer said in a statement.
The global test was introduced in July, aiming to add approximately 120 international sites and search for up to 30,000 participants in total.
More than 25,000 participants registered, BioNTech said, adding that it was still on track to seek approval from BNT162b2 next month.
Reporting through Ludwig Burger; edited through Thomas Seythal
All quotes were delayed for at least 15 minutes. See here for a complete list of operations and delays.
© 2020 Reuters. All rights are reserved.